Publications

by | September 21, 2012 | Uncategorized

Workshop on pharmaceutical products and their impact on the environment from a public health perspective

On 19 September 2012, BIO IS (Intelligent Service) organised a technical workshop (attended by EPHA) on the legislative and non-legislative factors influencing the presence of pharmaceuticals in the environment. According to two recent pieces of legislation (Directive 2010/84/EU and (Regulation 1235/2010/EU) on the applicable rules on pharmaceuticals, the pollution of waters and soils with pharmaceutical residues is not only an emerging environmental problem – it may also have a significant impact on public health.

Commissioned by the European Commission, BIO IS (Intelligent Service) will prepare a study by early 2013. This background evaluation will serve as a basic document for the Commission’s report.

The draft study presented by BIO IS served as the background document for discussion. Its main sections were:

  • emissions in the environment and contamination pathways,
  • environmental and human exposure,
  • impacts on the environment, and
  • possible factors of influence.

The main aims of the draft-study are the following:

  1. to provide an assessment of the scale and the trends
  2. to analyse the legislative and non-legislative factors possibly influencing the problem and
  3. to identify options to ameliorate the current framework and discuss the feasibility

The overall goal of the workshop was to present and discuss the collected evidence, and further seek inputs from stakeholders, Member States competent authorities, scientific experts, NGOs and industrial stakeholders.

There was a widely-shared consensus in the room that pharmaceutical pollution is an emerging issue given that the use of veterinary and pharmaceutical medicines is steadily increasing. There is also a need for better knowledge of medicinal substances (e.g. more data on the effects of drugs on environmental life, as in the cases of bio-accumulation and bio-degradation).

However, the need for further researches cannot justify inaction. There is enough evidence to take this problem seriously and take the necessary legal and non-legal steps to reduce the future release of this type of pollution into the environment. This approach is fully in line and underpinned by the precautionary principle, which ‘enables rapid response in the face of a possible danger to human, animal or plant health, or to protect the environment.’

Possible ways of action:

  • The industry could reduce the amount of waste production.
  • Health centres could also reduce pollution without specific waste treatment devices through promotion of good practices as in the case of the dumping of unused medicines.
  • Individuals may simply stop the flow of unused medicines into water and bin since the ideal solution would be reducing the consumption of medicines.

From EPHA’s perspective, this workshop was an opportunity to participate in a debate intended to shape the future form of this momentous study. Pharmacovigilance rules are necessary for the protection of public health in order to prevent, detect and assess adverse reactions to medicinal products sold on the Union market. Although this technical workshop focused mainly on the environmental impacts of pharmaceutical products, the public health community still remains concerned about the lack of human health related analyses and the possible effects of pharmaceutical residues on humans.

EPHA considers important to closely monitor the latest developments on this field. Together with the environmental health community, EPHA will contribute to this report in order to make the public health community’s voice heard in the final 2014 report.

On 2 January 2014 the Commission shall make public a report on the scale of the problem and consider whether amendments to Union legislation on medical products or other relevant legislation are necessary. By the same date, the Commission will make public an additional report on the performance of pharmacovigilance tasks.

—-
EPHA-related articles:

– Commissioner Dalli outlines strategy for pharmaceutical sector

– European Medicines Agency consultation on further GVP modules

– Unveiling the Health priorities of the Cyprus EU presidency

Get the EPHA Newsletter

The best of our activities, right in your inbox!